Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
Due to Coronavirus, a Virtual AIDSWatch 2020 Happened This Week—and Set a Record for Number of Attendees
AIDS United quickly revised the conference when it became clear that the COVID-19 crisis would shut down the longstanding IRL version.
Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Starting July 1, some HIV meds that are widely used will be excluded from their list.
Advocates say the move is more politics than science.
Best practices need to be replicated, but our health care structure will make doing so more challenging, says Ace Robinson of the Fast-Track Cities initiative.